CBR3 and breast carcinoma: Our study is based on the ceRNA hypothesis, that is, cbr3-as1 directly binds to miR-25-3p, thus targeting JNK1/MEK4, activating the MAPK pathway, and ultimately affecting the development of chemoresistance in breast cancer (Fig. 6).